Breaking News Instant updates and real-time market news.

VEEV

Veeva

$41.22

-0.06 (-0.15%)

, MSFT

Microsoft

$57.42

-0.18 (-0.31%)

07:05
10/04/16
10/04
07:05
10/04/16
07:05

Veeva announces integration of Veeva Vault with Microsoft Office Online

Veeva Systems (VEEV) announced the integration of Veeva Vault with Microsoft Office Online (MSFT) to unite cloud innovators and best-of-breed enterprise applications, delivering real-time, collaborative authoring in a compliant way.

VEEV

Veeva

$41.22

-0.06 (-0.15%)

MSFT

Microsoft

$57.42

-0.18 (-0.31%)

  • 05

    Oct

  • 06

    Oct

  • 16

    Oct

  • 23

    Oct

  • 14

    Nov

  • 30

    Nov

VEEV Veeva
$41.22

-0.06 (-0.15%)

08/31/16
PACS
08/31/16
NO CHANGE
PACS
Veeva price target raised to $42 from $35 at Pacific Crest
Pacific Crest analyst Brent Bracelin says that Veeva reported "strong" results. The analyst raised his estimates for the company to account for the impact of its new Vault products. He keeps an Overweight rating on the stock.
09/30/16
NEED
09/30/16
NO CHANGE
Target $46
NEED
Buy
Veeva price target raised to $46 after analyst day at Needham
Needham analyst Scott Berg said that after attending Veeva's analyst day meeting he believes that enthusiasm for stronger near-term sales opportunities was high. Noting that the company acknowledged it is tracking ahead of its CY20 operating model goals, Berg raised his price target on the stock to $46 from $43 and keeps a Buy rating on Veeva shares.
10/03/16
ADAM
10/03/16
NO CHANGE
Target $46
ADAM
Buy
Veeva price target raised to $46 from $43 at Canaccord
Canaccord analyst Richard Davis raised his price target on Veeva to $46 from $43 following its analyst day. The analyst believes Veeva has executed better than expected and expects the execution to continue. Davis reiterated his Buy rating on Veeva shares.
10/04/16
GSCO
10/04/16
INITIATION
Target $43
GSCO
Neutral
Veeva initiated with a Neutral at Goldman
Goldman analyst Jesse Hulsing initiated Veeva with a Neutral and a $43 price target due to premium valuation. .
MSFT Microsoft
$57.42

-0.18 (-0.31%)

09/06/16
RHCO
09/06/16
NO CHANGE
Target $18
RHCO
Neutral
SunTrust sees 'limited' list of Twitter suitors, says activist action unlikely
SunTrust analyst Robert Peck reiterated his belief that Twitter (TWTR) is unlikely to sell itself in 2016 in a new note to investors, but noted that investors have asked him who would be interested if Twitter were open to a sale. While giving his opinion on potential acquirers - which he sees possibly including Google (GOOG), Facebook (FB), Apple (AAPL), Amazon (AMZN), Microsoft (MSFT), AT&T (T), Verizon (VZ), Disney (DIS), Fox (FOXA), and Alibaba (BABA) - Peck said the company's high price and "unique" asset limit the potential buyers and gave his view that a PE buyer is highly unlikely given the company's lack of free cash flow. Additionally, Peck thinks activist action at Twitter seems "extremely unlikely" despite "unsubstantiated investor conjecture" and media reports. The analyst keeps Neutral rating and $18 price target on Twitter shares.
09/13/16
PACS
09/13/16
NO CHANGE
PACS
Microsoft cloud revenue could triple in four years, says Pacific Crest
Pacific Crest analyst Brent Bracelin says that Microsoft's cloud revenue "has the potential to triple in four years to $40B plus." The analyst thinks that the company could use artificial technology to create new "smart applications." He says the shares could exceed their all-time high of $58.72 and keeps a $65 price target and Overweight rating on the stock.
09/23/16
RHCO
09/23/16
NO CHANGE
RHCO
Buy
SunTrust says Twitter would help Salesforce deal with Microsoft
SunTrust analyst John Rizzuto believes a potential acquisition of Twitter (TWTR) could give Salesforce (CRM) a "strong external social platform" that can enhance its ecosystem while addressing the longer-term threat from Microsoft (MSFT). With less than $2B of cash on hand, Salesforce would need to raise much of the required capital as equity with a smaller debt component, Rizzuto tells investors in a research note. The analyst remains positive on Salesforce shares with a Buy rating. CNBC's David Faber reported earlier today that Twitter is getting closer to a sale and he named Salesforce as one of the potential suitors. Salesforce is down 5% to $70.69 while Twitter is up 19% to $22.12 in afternoon trading.
09/26/16
CANT
09/26/16
NO CHANGE
Target $42
CANT
Buy
Yelp takeout chances increased with share conversion, says Cantor
Yelp's (YELP) conversion of Class B super-voting shares into regular Class A shares late last week increases the company's takeout potential, Cantor Fitzgerald analyst Youssef Squali tells investors in a research note. Yelp, especially following recent improvements in the underlying growth fundamentals of the business, has become "an easier, and more likely" acquisition target, the analyst contends. The analyst views Facebook (FB), Priceline (PCLN), TripAdvisor (TRIP) and Microsoft (MSFT) as potential acquirers of Yelp. Squali estimates Yelp could be worth $53 per share in a takeout. He keeps a Buy rating on the stock with a $42 price target. The stock is up 2% to $40.35 in early trading.

TODAY'S FREE FLY STORIES

CORI

Corium

$10.88

0.03 (0.28%)

07:10
09/26/17
09/26
07:10
09/26/17
07:10
Initiation
Corium initiated  »

Corium initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

FDS

FactSet

$170.81

2.2 (1.30%)

07:10
09/26/17
09/26
07:10
09/26/17
07:10
Earnings
FactSet reports Q4 adj. EPS $1.90, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

LNG

Cheniere Energy

$44.12

0.64 (1.47%)

07:09
09/26/17
09/26
07:09
09/26/17
07:09
Initiation
Cheniere Energy initiated  »

Cheniere Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$4.37

0.15 (3.55%)

07:09
09/26/17
09/26
07:09
09/26/17
07:09
Hot Stocks
Chesapeake sees Q3 production 542,000 boe per day »

Chesapeake Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

KTOS

Kratos Defense

$12.72

-0.28 (-2.15%)

07:08
09/26/17
09/26
07:08
09/26/17
07:08
Hot Stocks
Kratos Defense receives $9.7M in contract awards »

Kratos Defense announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVGN

Evogene

$4.54

0.23 (5.34%)

07:08
09/26/17
09/26
07:08
09/26/17
07:08
Hot Stocks
Evogene reports 'positive' results in 2nd year field trials in banana »

Evogene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Axovant Phase 3 Alzheimer's study misses co-primary endpoints »

Axovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AST

Asterias

$3.25

0.05 (1.56%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Asterias receives regulatory clearance to start AST-VAC2 clinical trial »

Asterias Biotherapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MDXG

MiMedx

$12.35

-0.28 (-2.22%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
MiMedx announces confidential lawsuit settlement with terminated employee »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 13

    Nov

  • 14

    Nov

DRI

Darden

$83.14

0.26 (0.31%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Darden reports Q1 Olive Garden same-restaurant sales up 1.9% »

Reports Q1 same…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AGN

Allergan

$211.61

6.96 (3.40%)

07:05
09/26/17
09/26
07:05
09/26/17
07:05
Recommendations
Allergan analyst commentary  »

Allergan weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZRE

Azure Power

$16.18

0.18 (1.13%)

07:05
09/26/17
09/26
07:05
09/26/17
07:05
Hot Stocks
Azure Power awarded 260 MW solar project in Gujarat »

Azure Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEES

H&E Equipment

$26.97

-0.2 (-0.74%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Initiation
H&E Equipment initiated  »

H&E Equipment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$0.94

0.093 (10.98%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Hot Stocks
Northern Oil and Gas announces settlement with former CEO »

Northern Oil and Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Breaking Hot Stocks news story on Darden »

Darden reports Q1 Olive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BTX

BioTime

$2.72

-0.08 (-2.86%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
BioTime announces 'positive' secondary, long-term data from Renevia trial »

BioTime announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MBRX

Moleculin Biotech

$2.41

-0.07 (-2.82%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Moleculin Biotech announces FDA approval of Annamycin IND »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNCA

Genocea

$5.33

0.04 (0.76%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Downgrade
Genocea rating change  »

Genocea downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Darden reports Q1 blended same-restaurant sales from legacy brands up 1.7% »

Q1 same-restaurant sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Earnings
Darden backs FY18 adjusted cont ops EPS view $4.38-$4.50, consensus $4.47 »

The company reaffirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:01
09/26/17
09/26
07:01
09/26/17
07:01
Hot Stocks
Akebia saya Phase 2 vadadustat study confirmed findings from previous studies »

Akebia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

07:00
09/26/17
09/26
07:00
09/26/17
07:00
General news
FX Update: The dollar has been in rally mode »

FX Update: The dollar has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.